The published study about “Efficacy and safety assessment of nasal spray containing Sodium Hyaluronate and Methylsulfonylmethane (MSM) in otolaryngological disorders” focused on evaluating the antioxidant and anti-inflammatory capacities and the barrier effect of the patented technology.
This evaluation involved chemical assays centered on free radical inhibition and assays conducted on reconstructed respiratory epithelium inserts, where damage was induced using LPS. The results obtained indicate that, owing to the presence of sodium hyaluronate, methylsulfonylmethane, and N-acetyl cysteine, this technology could serve as a pharmacological tool for treating otolaryngological disorders and as a preventive measure against the risk of microbial contamination.
Our study aimed to investigate how a formulation containing all three components could encompass the recognized beneficial properties of each active ingredient and their potential use in otolaryngological conditions.
To this end, the study initially assessed the formulation’s anti-inflammatory and antioxidant capacity through instrumental analysis. The technology displayed excellent anti-inflammatory properties due to its nitric oxide-scavenging activity. The antioxidant capacity was confirmed through three evaluations: determining the total antioxidant activity (Molibdate assay), scavenging the DPPH radical, and scavenging the ABTS radical.
Subsequently, mucoadhesion and mucoprotection tests were conducted on reconstructed nasal mucosa tissue in vitro to demonstrate the technology’s efficacy on the nasal mucosa.For the evaluation of the mucoprotective capacity, the technique simulated an external insult to the nasal mucosa through LPS exposure. The efficacy of the sample was tested on reconstructed tissue after treatment with sodium hyaluronate, MSM, and sodium hyaluronate + MSM. The results revealed that both individual components and their combination had the ability to protect the tissue by reducing necrosis, cell degeneration, and erosion. This indicates Hyaluronic acid (HA) potential as an anti-inflammatory agent.
VINCENZO NOBILE R&D Director Complife
FABIO AMONE CEO Nutratech
MARIA FRANCESCA MOTTA In Vitro Safety and Efficacy Technician Nutratech
GIUSEPPE PULITANO Sales Manager Nutratech